TW202339764A - 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 - Google Patents

19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 Download PDF

Info

Publication number
TW202339764A
TW202339764A TW111150395A TW111150395A TW202339764A TW 202339764 A TW202339764 A TW 202339764A TW 111150395 A TW111150395 A TW 111150395A TW 111150395 A TW111150395 A TW 111150395A TW 202339764 A TW202339764 A TW 202339764A
Authority
TW
Taiwan
Prior art keywords
sleep
compound
individual
administered
effective amount
Prior art date
Application number
TW111150395A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆士 Ｊ 多赫提
史帝芬 傑 凱恩思
杰佛瑞 Ｍ 強納斯
英德吉 考爾
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202339764A publication Critical patent/TW202339764A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111150395A 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 TW202339764A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762558703P 2017-09-14 2017-09-14
US62/558,703 2017-09-14
US201862624678P 2018-01-31 2018-01-31
US201862624680P 2018-01-31 2018-01-31
US62/624,678 2018-01-31
US62/624,680 2018-01-31
US201862653189P 2018-04-05 2018-04-05
US62/653,189 2018-04-05

Publications (1)

Publication Number Publication Date
TW202339764A true TW202339764A (zh) 2023-10-16

Family

ID=65723895

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111150395A TW202339764A (zh) 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法
TW107132510A TW201919642A (zh) 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107132510A TW201919642A (zh) 2017-09-14 2018-09-14 19去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法

Country Status (9)

Country Link
US (3) US20220110949A1 (https=)
EP (3) EP4218767A1 (https=)
JP (3) JP2020534270A (https=)
AU (2) AU2018334214A1 (https=)
CA (1) CA3075872A1 (https=)
IL (2) IL303083A (https=)
MX (3) MX2020002889A (https=)
TW (2) TW202339764A (https=)
WO (1) WO2019055764A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
KR20220112803A (ko) * 2019-12-05 2022-08-11 세이지 테라퓨틱스, 인크. 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) * 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
EP3504189A1 (en) * 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
WO2019051264A1 (en) * 2017-09-07 2019-03-14 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS AND METHODS OF USE

Also Published As

Publication number Publication date
MX2023010063A (es) 2023-09-06
JP2023038310A (ja) 2023-03-16
WO2019055764A1 (en) 2019-03-21
IL303083A (en) 2023-07-01
US20230201224A1 (en) 2023-06-29
AU2024205601A1 (en) 2024-08-29
CA3075872A1 (en) 2019-03-21
EP4696301A3 (en) 2026-04-29
AU2018334214A1 (en) 2020-03-26
EP4218767A1 (en) 2023-08-02
US20250387414A1 (en) 2025-12-25
EP3681510A1 (en) 2020-07-22
MX2020002889A (es) 2020-10-01
MX2023010064A (es) 2023-09-06
JP2024107137A (ja) 2024-08-08
JP2020534270A (ja) 2020-11-26
US20220110949A1 (en) 2022-04-14
TW201919642A (zh) 2019-06-01
IL273126A (en) 2020-04-30
EP4696301A2 (en) 2026-02-18

Similar Documents

Publication Publication Date Title
US20250387414A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025169279A (ja) 睡眠時無呼吸を治療する方法及び組成物
CN114340670B (zh) T-型钙通道调节剂的制剂及其使用方法
TW202133863A (zh) １９—ｎｏｒ—ｃ３，３—二取代—ｃ２１—ｎ—吡唑基類固醇及使用其之方法
TW202341995A (zh) 用於治療cns相關病症之神經活性類固醇
JP2025084754A (ja) 睡眠時無呼吸を治療するための方法および組成物
JP2025542596A (ja) 乳分泌中の女性にソルリアムフェトルを投与する方法
HK40096830A (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20220305012A1 (en) Lemborexant for treating sleep issues
RU2844395C2 (ru) Лемборексант для лечения проблем со сном
EP4673123A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
EP3989976A1 (en) Lemborexant for treating sleep issues
KR20250165616A (ko) 고함량 단일 투여 단위 제형 및 이의 사용 방법
JP2025536721A (ja) 強迫性障害の予防または治療のための低用量のドネペジルまたはその誘導体を使用した新規投与レジメン
WO2020263331A1 (en) Lemborexant for treating sleep issues
TW202508553A (zh) 用於預防、減緩或治療睡眠障礙及／或與睡眠障礙相關之疾病的方法
JP2025116005A (ja) 睡眠問題の治療のためのレンボレキサント
CN117769423A (zh) 莱博雷生用于在治疗与神经系统变性疾病相关的不规律睡眠觉醒节律紊乱和昼夜节律性睡眠障碍的方法中使用
Vinogradov et al. Insomnia and Sleep-Related Breathing Disorders: New Risk Factors for Ischemic Stroke
Parkes et al. Disorders of Sleep and Wakefulness
HK1145282B (en) Treatment of sleep disorders
HK1145282A1 (en) Treatment of sleep disorders